2018年
Lysine-specific demethylase 1 inhibitors prevent teratoma development from human induced pluripotent stem cells
Oncotarget
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- ,
- 巻
- 9
- 号
- 5
- 開始ページ
- 6450
- 終了ページ
- 6462
- 記述言語
- 英語
- 掲載種別
- 研究論文(学術雑誌)
- DOI
- 10.18632/oncotarget.24030
- 出版者・発行元
- Impact Journals LLC
Human induced pluripotent stem cells (hiPSCs) are creating great expectations for regenerative medicine. However, safety strategies must be put in place to guard against teratoma formation after transplantation of hiPSC-derived cells into patients. Recent studies indicate that epigenetic regulators act at the initial step of tumorigenesis. Using gain-of-function and loss-of-function approaches, we show here that the expression and function of lysine-specific demethylase 1 (LSD1) are tightly regulated in hiPSCs, and their deregulation underlies the development of teratomas. Consistent with these results, we demonstrate that an LSD1 inhibitor, S2157, prevented teratoma formation from hiPSCs transplanted into immunodeficient mice. This novel action of LSD1 and the effects of its inhibition potentially allow for the development of new clinical applications and therapeutic strategies using hiPSCs.
- リンク情報
- ID情報
-
- DOI : 10.18632/oncotarget.24030
- ISSN : 1949-2553
- PubMed ID : 29464084
- SCOPUS ID : 85040640484